EGFR and gastric cancer: For example, lapatinib, which is a small molecule tyrosine kinase inhibitor (TKI) of HER1 (EGFR) and HER2, lacked significant antitumor efficacy in HER2-positive advanced GC in both 1L (TRIO-013/LOGiC trial) and 2L (TyTAN trial) settings [83,84].